NEW YORK (GenomeWeb) – Qiagen and HTG Molecular Diagnostics have agreed to a second development program under their previously announced master assay development, commercialization, and manufacturing agreement.
As part of the program announced today, HTG Molecular and Qiagen Manchester, a wholly owned subsidiary of Qiagen, will use HTG EdgeSeq technology to develop gene expression profiling assays for use with next-generation sequencing technology to support an unnamed pharmaceutical company's therapeutic development and commercialization programs.
"We are very pleased with the early results of our partnership with Qiagen and are encouraged by customer reception to our joint capabilities, which provide a complete NGS solution from biomarker development to full companion diagnostic commercialization," HTG President and CEO TJ Johnson said in a statement.
"With two new programs realized from the Qiagen partnership to date, HTG now has three distinct clinical assay development programs underway, including two that we believe could lead to regulatory filings for companion diagnostics during 2018," Johnson added.